• Explore /
  • Poster
  • / Efficacy and safety of polymeric micelle paclitaxel (pm-Pac) plus tislelizumab and carboplatin for first-line treatment of patients with advanced squamous non-small-cell lung cancer.

Efficacy and safety of polymeric micelle paclitaxel (pm-Pac) plus tislelizumab and carboplatin for first-line treatment of patients with advanced squamous non-small-cell lung cancer.

Abstract Poster

Authors

null

Meiqi Shi

Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Meiqi Shi , Yufang Zhao , Li Wang , Wei Peng , Xiangzhi Zhu , Xingwang Li , Lv-hui Wang , An-mei Ma , Yi-qun Tang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9036)

DOI

10.1200/JCO.2023.41.16_suppl.9036

Abstract #

9036

Poster Bd #

24

Abstract Disclosures

Similar Posters

First Author: Jianqing Zhu

First Author: Panpan Zhang

First Author: Jun Ni

First Author: TAO Haitao